For the treatment of adults with moderately to severely active Crohn’s disease who have failed or were intolerant to conventional therapy (but never failed treatment with a TNF blocker) or have failed or were intolerant to treatment with one or more TNF blockers
STELARA® Dosing Is Uniquely Designed for Crohn’s Disease1
A Single IV induction
Single IV induction dose administered over at least 1 hour
|Body weight* of patient at the time of dosing||Dose||
Number of 130 mg/26 mL
(5 mg/mL) STELARA® vials
|55 kg or less||260 mg||2|
|more than 55 kg to 85 kg||390 mg||3|
|more than 85 kg||520 mg||4|
*Approximately 2.2 pounds per kilogram.
6 subQ maintenance doses during Year 1
90-mg dose every 8 weeks after induction dose
For optimal outcome, STELARA® should be dosed and administered as described in the Prescribing Information.
- Please refer to the Dosage and Administration section of the Prescribing Information for complete information on how to prepare and administer STELARA®
- STELARA® is intended for use under the guidance and supervision of a physician with patients who will be closely monitored and have regular follow-up
- Patients may self-inject with STELARA® after physician approval and proper training
- Patients should be instructed to follow the direction provided in the Medication Guide
Write 2 Prescriptions for STELARA® (ustekinumab)1
One for the Single Intravenous (IV) Induction Dose* and 1 for Subcutaneous (subQ) Maintenance Treatment
STELARA® IV Induction
STELARA® SubQ Maintenance
*The single IV infusion dose and number of vials are determined using a weight-based dosage regimen: STELARA® 260 mg (weight ≤55 kg), STELARA® 390 mg (weight >55 kg and ≤85 kg), and STELARA® 520 mg (weight >85 kg). Please refer to the full Prescribing Information for the complete dosing information.
A Convenient Maintenance Dosing Schedule
7 doses of STELARA® in the first year1
Single intravenous (IV) weight-based induction dose administered over at least 1 hour
6 subcutaneous (subQ) injection maintenance doses of 90 mg (1 every 8 weeks after induction dose)
STELARA® (ustekinumab) is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have:
- failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed treatment with a tumor necrosis factor (TNF) blocker, or
- failed or were intolerant to treatment with one or more TNF blockers.
27 doses of Humira® in the first year2
3 starter injections of 80 mg in 2 doses
25 subQ injection maintenance doses of 40 mg (1 every other week thereafter)
Humira® (adalimumab) is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. Humira® is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.2
This is not intended to compare the safety, effectiveness, or uses of these treatments. Please refer to each product’s Prescribing Information for recommended dosing and administration. Humira® is a registered trademark of AbbVie Inc.
STELARA® Recommended Dosing for Crohn's Disease: Induction dose—A single IV infusion using a weight-based dosage regimen: 260 mg (weight 55 kg or less), 390 mg (weight more than 55 kg to 85 kg), 520 mg (weight more than 85 kg). Maintenance dose—A subQ 90-mg dose administered every 8 weeks after the induction dose.1
Humira® Recommended Dosing for Crohn's Disease: 160 mg initially on Day 1 (given in 1 day or split over 2 consecutive days), followed by 80 mg 2 weeks later (Day 15). Two weeks later (Day 29), begin a maintenance dose of 40 mg every other week.2